Indication: Gastrooesophageal Cancer

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

HER2-negative, locally adv unresectable metastatic

Sub-indication: Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) denocarcinoma

Line of Therapy: 1st line with CLDN 18.2, HER2-

Drug Study

Principal Investigator: Michael Driscoll, M.D.
Norton Cancer Institute

Sponsor: Astellas Pharma US, Inc

Learn more at ClinicalTrials.gov

Email for more information: GI-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.